Showing 5911-5920 of 8181 results for "".
- Oral Roflumilast Suppresses Psoriatic Inflammation at the Gene and Cellular Level: Studyhttps://practicaldermatology.com/news/oral-roflumilast-suppresses-psoriatic-inflammation-at-the-gene-and-cellular-level/2484789/In a mechanistic substudy of the PSORRO trial, oral roflumilast demonstrated targeted immunomodulatory effects in patients with moderate-to-severe plaque psoriasis. Researchers for the vivo analysis sourght to characterize the dru
- MEL-SELF Analysis: Comparable Outcomes Between Affordable and Premium Dermatoscopeshttps://practicaldermatology.com/news/analysis-shows-comparable-outcomes-between-affordable-and-premium-dermatoscopes/2484733/A new randomized study embedded within the MEL-SELF trial suggests both low-cost and high-cost dermatoscopes enabled patients with a history of early-stage melanoma to effectively capture images for remote dermatologic assessment.
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de
- Report: Antibiotics Linked to Shorter Biologic Persistence in Psoriasishttps://practicaldermatology.com/news/report-antibiotics-linked-to-shorter-biologic-persistence-in-psoriasis/2484451/Antibiotic exposure is associated with reduced persistence of biologic therapies in patients with psoriasis, according to findings from a nationwide French cohort study published in JAMA Dermatology.
- Remibrutinib Outperforms Placebo in Chronic Spontaneous Urticaria Control: Studyhttps://practicaldermatology.com/news/remibrutinib-outperforms-placebo-in-chronic-spontaneous-urticaria-control-study/2484429/Remibrutinib showed rapid and sustained efficacy in adults with chronic spontaneous urticaria (CSU) in a pooled analysis of the phase 3 REMIX-1 and REMIX-2 studies. The multicenter, double-blind, placebo-controlled trials looke
- Large Study Shows No Link Found Between Pemphigus and Psychiatric Disordershttps://practicaldermatology.com/news/large-study-shows-no-link-found-between-pemphigus-and-psychiatric-disorders/2484421/Results from a large retrospective cohort study analyzing more than 120 million U.S. electronic health records found no increased risk of psychiatric disorders in patients with pemphigus. "While 10–15% of dermatology patients ar
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- FDA Approves Restylane Lyft for Chin Augmentation in Adultshttps://practicaldermatology.com/news/fda-approves-restylane-lyft-for-chin-augmentation-in-adults/2484326/Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Restylane® Lyft™ with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion.